Twice-yearly drug eases symptoms in chronic rhinosinusitis with polyps
An international collaboration of researchers, sponsored by GSK and working on behalf of the ANCHOR-1 and ANCHOR-2 trial investigators, conducted two Phase III clinical trials to evaluate depemokimab, an ultra-long-acting anti-IL-5 biologic drug, for chronic rhinosinusitis with nasal polyps.
Results demonstrate that depemokimab significantly improves total nasal polyps score and nasal obstruction symptoms while maintaining a safety profile comparable to placebo.
Chronic rhinosinusitis with nasal polyps is characterized by persistent inflammation of the nasal and paranasal mucosa, leading to severe nasal obstruction, sinus pressure, loss of smell, and recurrent infections. Current treatments involve intranasal corticosteroids, short-term systemic corticosteroids for symptom exacerbations, and surgical removal of nasal polyps.
